

WHAT ID IS DOING TO PRESERVE ANTIBIOTICS

The rapid increase of antibiotic resistance coupled with no new drugs to treat infections has created a perfect storm.

Every current antibiotic is a derivative of one discovered **before 1982.**



\$1.8 billion
Antimicrobial venture capital investment

\$38 billion
Total pharmaceutical venture capital investment

Less than 5% of pharmaceutical venture capital goes to antimicrobials.



Most major drug companies have **reduced or quit** antibiotic research and development. Compared to other types of drugs, antibiotics to treat resistant infections are difficult to develop.



Sales of antibiotics are **small** compared to other pharmaceuticals.

AVYCAZ (antibiotic) **\$75 million** in sales 2 years post launch

MOST OTHER DRUGS **\$500 million** to **\$1 billion** in sales 2 years post launch

ID'S RESPONSE

As new infectious diseases threats continue to emerge, we need a robust, renewable antibiotic pipeline to meet current and future patient and public health needs.

- **Remove barriers to developer entry** by affecting the cost of R&D investments
- **Provide incentives that offer financial return** after a technology has been developed

Learn more: www.ValueofID.org